Spotlight

Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had granted Orphan Drug Designation to BPS-804 for osteogenesis imperfecta, a rare, chronic genetic

As part of the deal, Adynxx stockholders will become the majority owners of Alliqua’s outstanding common stock on a fully-diluted basis. The public clinical-stage pharmaceutical firm will involve

The confirmation came from the new sub-analysis data from the Euro-Esli study of eslicarbazepine acetate for focal-onset seizures in more than 2,000 patients. Bial and Eisai said that

Chronocort was not successful in confirming its superiority over conventional treatment in endocrine control over a 24-hour period during the late-stage clinical trial held in Europe. Diurnal Group

The regulators have accepted the firm’s filings for investigational oral and once-daily siponimod to treat secondary progressive multiple sclerosis (SPMS) in adults. Siponimod is an investigational and selective

ARO-HBV is the third generation subcutaneously administered RNA interference (RNAi) therapeutic of Arrowhead being developed as a potential curative therapy for patients with chronic HBV infection. The companies

As per terms of the deal, Roche will secure worldwide and exclusive license from GO Therapeutics for cancer-specific targeting antibodies. The license will allow Roche to develop and

The newly licensed Xonvea, which is a combination of doxylamine and pyridoxine, will be available across the country for women having NVP where conservative management was not successful.

Feraccru already has an approval for the indication in adults in the European Union. In Switzerland, the drug has been approved for the treatment of iron deficiency anaemia